TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
TScan Therapeutics Price Performance
Shares of NASDAQ:TCRX opened at $5.64 on Friday. TScan Therapeutics, Inc. has a 1-year low of $2.14 and a 1-year high of $9.69. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The stock’s fifty day simple moving average is $6.30 and its two-hundred day simple moving average is $7.17. The stock has a market cap of $298.75 million, a PE ratio of -4.41 and a beta of 0.83.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. As a group, analysts forecast that TScan Therapeutics, Inc. will post -1.17 EPS for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Analysis on TScan Therapeutics
Institutional Investors Weigh In On TScan Therapeutics
Several large investors have recently made changes to their positions in TCRX. Vanguard Group Inc. grew its position in TScan Therapeutics by 1.1% during the first quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after buying an additional 20,000 shares during the period. Great Point Partners LLC bought a new stake in shares of TScan Therapeutics in the 2nd quarter worth approximately $5,504,000. Marshall Wace LLP lifted its stake in TScan Therapeutics by 60.8% in the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after purchasing an additional 116,316 shares during the last quarter. Tocqueville Asset Management L.P. bought a new position in TScan Therapeutics during the first quarter valued at $1,685,000. Finally, abrdn plc purchased a new stake in TScan Therapeutics in the fourth quarter worth $1,166,000. 82.83% of the stock is owned by hedge funds and other institutional investors.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
See Also
- Five stocks we like better than TScan Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Using the MarketBeat Dividend Yield Calculator
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Insider Buying Explained: What Investors Need to Know
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.